Emergent BioSolutions

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EBS and other ETFs, options, and stocks.

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. 

CEO
Joseph C. Papa
CEOJoseph C. Papa
Employees
900
Employees900
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1998
Founded1998
Employees
900
Employees900

EBS Key Statistics

Market cap
640.74M
Market cap640.74M
Price-Earnings ratio
9.42
Price-Earnings ratio9.42
Dividend yield
Dividend yield
Average volume
879.15K
Average volume879.15K
High today
$12.64
High today$12.64
Low today
$12.06
Low today$12.06
Open price
$12.24
Open price$12.24
Volume
582.14K
Volume582.14K
52 Week high
$13.41
52 Week high$13.41
52 Week low
$4.02
52 Week low$4.02

Stock Snapshot

With a market cap of 640.74M, Emergent BioSolutions(EBS) trades at $12.20. The stock has a price-to-earnings ratio of 9.42.

As of 2025-12-17, Emergent BioSolutions(EBS) stock has fluctuated between $12.06 and $12.64. The current price stands at $12.20, placing the stock +1.2% above today's low and -3.5% off the high.

Emergent BioSolutions(EBS) shares are trading with a volume of 582.14K, against a daily average of 879.15K.

During the past year, Emergent BioSolutions(EBS) stock moved between $4.02 at its lowest and $13.41 at its peak.

During the past year, Emergent BioSolutions(EBS) stock moved between $4.02 at its lowest and $13.41 at its peak.

EBS News

TipRanks 2d
Emergent BioSolutions Receives Buy Rating Amid Strategic Milestones and Strong Market Position

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Emergent Biosolutions today and set a price target of $15.00. Claim 50% Off TipRanks Premium an...

TipRanks 6d
Emergent BioSolutions Gains FDA Approval for Winnipeg Facility

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

TipRanks 6d
Emergent BioSolutions receives FDA approval for raxibacumab manufacturing

Emergent BioSolutions (EBS) announced that the U.S. Food and Drug Administration has approved its supplemental Biologics License Application for its Winnipeg, C...

People also own

Based on the portfolios of people who own EBS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.